Cellectar Biosciences Inc [CLRB] stock is trading at $3.71, up 6.30%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CLRB shares have lost -0.27% over the last week, with a monthly amount glided 2.20%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, March 2024, Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update. In a post published today on Yahoo Finance, Management to host a conference call today at 8:30 am ET.
From an analyst’s perspective:
On September 13, 2019, ROTH Capital initiated with a Buy rating. Ladenburg Thalmann started tracking the stock assigning a Buy rating and suggested a price target of $2.70 on December 21, 2016.
Cellectar Biosciences Inc [CLRB] stock has fluctuated between $1.30 and $4.45 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Cellectar Biosciences Inc [NASDAQ: CLRB] shares were valued at $3.71 at the most recent close of the market. An investor can expect a potential return of 223.45% based on the average CLRB price forecast.
Analyzing the CLRB fundamentals
Gross Profit Margin for this corporation currently stands at 0.29% with Operating Profit Margin at -117.93%, Pretax Profit Margin comes in at -115.16%, and Net Profit Margin reading is -114.6%. To continue investigating profitability, this company’s Return on Assets is posted at -3.14, Equity is 19.31 and Total Capital is 45.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.56 points at the first support level, and at 3.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.80, and for the 2nd resistance point, it is at 3.88.
Cellectar Biosciences Inc [CLRB] reported earnings per share of -$1.28 for its fiscal quarter that ended on 9/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.21/share, meaning a difference of -$0.07 and a surprise factor of -5.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2022 were -$1.22 per share as compared to estimates of -$1.03 per share, a difference of -$0.19 representing a surprise of -18.40%.
Ratios To Look Out For
For context, Cellectar Biosciences Inc’s Current Ratio is 0.81. In addition, the Quick Ratio stands at 0.81 and the Cash Ratio stands at 0.74.
